All In MedTech

FDA Clearance Tracker · P030017-S344

Precision Spectra Spinal Cord Stimulator (SCS) System, Precision Novi Spinal Cord Stimulator (SCS) System, Precision Mon

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 12, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P030017-S344
Device name
Precision Spectra Spinal Cord Stimulator (SCS) System, Precision Novi Spinal Cord Stimulator (SCS) System, Precision Mon
Applicant location
Valencia, CA
Received
Apr 19, 2021
Decided
Jul 12, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P030017

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for an update to the existing Software Bionic Navigator 3D version 4.0 to version 4.1. The updated software will be installed on the Clinician Programmer using the Bionic Navigator (BN) 3D 4.1 Installer (Model # SC-7101-410). This would allow one single software version (BN3D 4.1) to support all the Precision Spectra, Precision Novi, Precision Montage MRI, and Spectra WaveWriter and WaveWriter Alpha BCS Stimulators. The user interface of BN 3D 4.1 remain the same except for translations into various languages to support the international markets. In addition, BN 3D 4.1 introduces a new Sequence feature for additional flexibility when programming WaveWriter Alpha stimulators, in which a Sequence composed of various blocks of pulses can be created using a Composer tool and applied to the stimulators in a Programming Mode called Sequence Mode.The BN 3D software will be updated to Version 4.1 so that one single software version (BN3D 4.1) can support all the Precision Spectra, Precision Novi, Precision Montage MRI, and Spectra WaveWriter and WaveWriter Alpha BCS Stimulators. The user interface of BN 3D 4.1 will remain the same except for translations into various languages to support the international markets. In addition, BN 3D 4.1 introduces a new Sequence feature for additional flexibility when programming WaveWriter Alpha stimulators, in which a Sequence composed of various blocks of pulses can be created using a Composer tool and applied to the stimulators in a Programming Mode called Sequence Mode. Note that the new Sequence feature is only applicable to WaveWriter Alpha stimulators. The existing programming features for all stimulators remain the same.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.